Ivermectin Fails to Show Cancer Efficacy, Despite Influencer Claims

The repurposing of existing drugs for new indications is a legitimate and often fruitful area of research, but it demands the same stringent scientific scrutiny as novel compounds. Ivermectin, an avermectin derivative, has a well-established role in treating parasitic infections such as onchocerciasis and strongyloidiasis. Its mechanism of action in parasites involves binding to glutamate-gated chloride channels, leading to hyperpolarisation and paralysis of the invertebrate muscle and nerve cells. This mechanism, however, does not directly translate to antineoplastic activity in human cells, which lack these specific channels.

The current enthusiasm for ivermectin as an anticancer agent stems primarily from a collection of preclinical studies, mostly conducted in vitro and in animal models. These studies, often cited by proponents, explore various proposed mechanisms, including inhibition of the Wnt/β-catenin pathway, induction of apoptosis, disruption of mitochondrial function, and modulation of inflammatory responses. For example, some cell line studies report that ivermectin can inhibit proliferation and induce cell death in various cancer types, including breast, colon, and ovarian cancers. Other preclinical work suggests it might sensitise cancer cells to chemotherapy or radiation. But these laboratory observations, while a necessary first step in drug discovery, are a considerable distance from clinical utility.

The gap between petri dish and patient

The fundamental issue with extrapolating preclinical ivermectin data to human cancer treatment lies in the pharmacokinetics and pharmacodynamics. The concentrations of ivermectin required to achieve significant anticancer effects in vitro are often in the micromolar range. Human pharmacokinetic studies, primarily conducted for its antiparasitic indications, show that standard oral doses (e.g., 0.2 mg/kg) result in peak plasma concentrations in the low nanomolar range, typically around 50-100 ng/mL (approximately 0.08-0.17 µM). This represents a substantial, often several-fold, difference between the concentrations effective in a petri dish and those safely achievable in a human patient. Achieving micromolar concentrations in human plasma would necessitate doses far exceeding those approved for parasitic infections, likely leading to severe toxicity.

Despite the preclinical intrigue, robust human clinical trials evaluating ivermectin as a primary or adjunctive cancer therapy are conspicuously absent. A search of major clinical trial registries reveals a handful of small, early-phase studies, mostly observational or pilot in nature, with very limited patient numbers. These studies generally lack the rigorous design, randomisation, blinding, and statistical power necessary to draw definitive conclusions about efficacy. For instance, some investigators have explored ivermectin in combination with standard chemotherapy in small cohorts of patients with advanced malignancies. These trials, often open-label, report anecdotal improvements or stable disease, but without a control arm, attributing any benefit specifically to ivermectin is impossible. The natural history of many cancers, coupled with the variability in patient response to standard treatments, makes such uncontrolled observations unreliable.

One of the more frequently referenced areas of preclinical research involves ivermectin's potential to inhibit the PAK1 kinase, a protein implicated in cancer cell growth and survival. While PAK1 inhibition is an attractive therapeutic target, demonstrating this effect at clinically relevant ivermectin concentrations in human tumours has not occurred. Similarly, claims of ivermectin's ability to target cancer stem cells or reverse multidrug resistance remain largely confined to laboratory models, with no translation to improved patient outcomes in controlled clinical settings. The complexity of tumour biology, with its myriad compensatory pathways and heterogeneous cell populations, means that a single agent rarely achieves the broad, sustained effects seen in simplified in vitro systems.

The safety profile of ivermectin at standard antiparasitic doses is generally favourable, but this does not extend to the much higher doses that would theoretically be needed for anticancer effects. Common side effects at approved doses include dizziness, nausea, diarrhoea, and skin rash. At supratherapeutic doses, central nervous system toxicity, including seizures and coma, becomes a significant concern. Hepatotoxicity has also been reported. Administering ivermectin at doses sufficient to reach micromolar plasma concentrations would likely induce unacceptable levels of toxicity, far outweighing any unproven benefit. This risk-benefit imbalance is a critical consideration that online proponents routinely ignore.

The spread of misinformation regarding ivermectin's anticancer properties mirrors earlier narratives surrounding its use for COVID-19. In both instances, a drug with a known mechanism for one indication was enthusiastically promoted for an entirely different, complex disease based on weak preclinical signals and anecdotal reports, bypassing the established hierarchy of evidence. This pattern highlights a broader challenge in medical communication: the public's desire for simple solutions to complex problems, often amplified by social media algorithms that prioritise engagement over accuracy. For patients facing a cancer diagnosis, the allure of a readily available, inexpensive drug, especially one framed as an alternative to arduous conventional treatments, can be powerful and dangerous.

The regulatory landscape for drug approval is designed precisely to prevent such premature adoption. Agencies like the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA) require robust evidence from well-designed, adequately powered clinical trials to demonstrate both efficacy and safety for a specific indication. Ivermectin has not undergone, nor has it passed, this rigorous process for any cancer indication. Its use for cancer outside of a formal, ethics-approved clinical trial is off-label and unsupported by evidence, placing the prescribing clinician in a precarious position and the patient at considerable risk.

The absence of large-scale, randomised, placebo-controlled trials for ivermectin in oncology is not an oversight; it reflects the lack of compelling early-phase data that would justify such substantial investment. Pharmaceutical companies and academic institutions typically advance compounds to expensive Phase II and III trials only after strong signals emerge from Phase I safety studies and robust Phase II efficacy signals. Ivermectin has not generated these signals for cancer. The ongoing promotion of ivermectin as a cancer miracle drug, therefore, constitutes a significant disservice to patients, diverting them from therapies with proven benefits and potentially exposing them to harm.